Vets at Ohio State University are working with biotech firm Karyopharm to bring a new cancer therapy to market for dogs and people. They recently announced that the U.S. Food & Drug Administration had approved the drug for compassionate use in dogs with lymphoma–the first new option for dogs with the disease in more than two decades. Veterinarians will have limited access to the drug while the company works to complete the clinical trials necessary for a full approval.
OSU veterinarian Cheryl London led the trials of the drug, which works by preventing tumor-suppressing proteins from exiting the nucleus of cells–an action that normally allows cancer to grow out of control.
Read more here.